Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat domain-containing protein 31 (ANKRD31) is a scaffold protein characterized by multiple ankyrin repeats that facilitate protein-protein interactions in meiotic cells[1][2][3][4][5]. ANKRD31 plays an essential role in initiating meiotic recombination by anchoring double-strand break-promoting factors, especially REC114, to specific locations on chromosomes, including pseudoautosomal regions of sex chromosomes[1][2][4][5]. Loss or dysfunction of ANKRD31 leads to misregulation of double-strand break formation, defective recombination, male meiotic arrest and infertility, and reduced oocyte reserve in females[1][2][4][5]. ANKRD31 is not considered a canonical therapeutic target such as a receptor, enzyme, or transporter, but instead serves as a critical scaffold for meiotic chromosomal events. There are no known drugs directly targeting ANKRD31, and no established roles in cancer, inflammation, or other complex diseases outside germ cell development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat domain-containing protein 31 (ANKRD31).